|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 318.20 SEK | -1.85% |
|
+0.89% | +59.50% |
| 12-09 | Stockholm Bullets - Lundin Gold Drops After New Gold Forecast | FW |
| 12-09 | Bioarctic's Leqembi Added to China's Commercial Insurance Innovative Drug List | FW |
| Capitalization | 28.21B 3.04B 2.58B 2.41B 2.26B 4.18B 276B 4.58B 10.88B 130B 11.4B 11.16B 470B | P/E ratio 2025 * |
27.7x | P/E ratio 2026 * | 95.9x |
|---|---|---|---|---|---|
| Enterprise value | 26.18B 2.82B 2.4B 2.24B 2.1B 3.88B 256B 4.25B 10.1B 120B 10.58B 10.36B 437B | EV / Sales 2025 * |
13x | EV / Sales 2026 * | 21.9x |
| Free-Float |
44.08% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BioArctic AB
| 1 day | -1.85% | ||
| 1 week | +0.89% | ||
| Current month | +4.46% | ||
| 1 month | +7.94% | ||
| 3 months | +17.85% | ||
| 6 months | +59.50% | ||
| Current year | +59.50% |
| 1 week | 314 |  | 325.8 |
| 1 month | 275.8 | | 328.6 |
| Current year | 154.4 | | 342.8 |
| 1 year | 154.4 | | 342.8 |
| 3 years | 137.7 | | 392 |
| 5 years | 66.7 | | 392 |
| 10 years | 20.4 | | 392 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 31/12/2012 | |
| Director of Finance/CFO | 54 | 31/05/2023 | |
Johanna Fälting
CTO | Chief Tech/Sci/R&D Officer | 53 | 31/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23/01/2003 | |
| Chairman | 76 | 27/01/2003 | |
Eugen Steiner
CHM | Chairman | 71 | 31/05/2023 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.25% | 4 M€ | +21.26% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.85% | +0.89% | +83.72% | +5.64% | 3.04B | |
| -0.80% | -4.17% | -4.91% | +15.33% | 45.88B | |
| -0.87% | +1.66% | +12.48% | +8.78% | 37.75B | |
| -2.05% | -4.51% | +72.58% | +48.44% | 33.67B | |
| -1.17% | -0.91% | +3.30% | +17.76% | 27.58B | |
| -0.07% | +2.69% | +59.76% | +171.23% | 15.74B | |
| -1.82% | -0.32% | +73.47% | +219.18% | 14.99B | |
| -1.04% | +0.64% | -10.64% | -2.39% | 13.93B | |
| -0.53% | +7.87% | +55.28% | +78.84% | 12.96B | |
| -1.74% | -0.62% | +105.70% | +102.72% | 12.69B | |
| Average | -0.91% | +0.41% | +45.07% | +66.55% | 21.82B | |
| Weighted average by Cap. | -0.94% | -0.64% | +32.02% | +52.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.02B 217M 184M 173M 162M 298M 19.74B 327M 777M 9.27B 814M 797M 33.61B | 1.2B 130M 110M 103M 96.66M 178M 11.8B 196M 465M 5.54B 487M 477M 20.09B |
| Net income | 1B 108M 91.94M 86.01M 80.62M 149M 9.84B 163M 388M 4.62B 406M 398M 16.76B | 294M 31.69M 26.92M 25.18M 23.6M 43.56M 2.88B 47.74M 113M 1.35B 119M 116M 4.91B |
| Net Debt | -2.03B -219M -186M -174M -163M -300M -19.87B -329M -783M -9.34B -820M -803M -33.84B | -1.8B -194M -165M -154M -145M -267M -17.64B -292M -695M -8.29B -728M -713M -30.04B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/12/25 | 318.20 kr | -1.85% | 100,202 |
| 15/12/25 | 324.20 kr | +1.19% | 193,406 |
| 12/12/25 | 320.40 kr | -0.25% | 109,233 |
| 11/12/25 | 321.20 kr | +1.71% | 199,012 |
| 10/12/25 | 315.80 kr | +0.13% | 152,933 |
Delayed Quote Nasdaq Stockholm, December 16, 2025 at 05:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOA B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition